Yazar "Bal, Tayibe" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The high rate of Candida parapsilosis candidemia among non-burn patients with polytrauma in the surgical intensive care units of a university hospital
    (2020) Bal, Tayibe; Cabalak, Mehmet; Ozer, Burcin; Comez, Mehmet Selim; Onlen, Yusuf
    Aim: Candidemia is a life-threatening infection that has been reported to be associated with poorer outcomes in trauma patients. The present study aimed to investigate the epidemiology of candidemia in non-burn patients with polytrauma. Material and Methods: We conducted a retrospective, single-center, observational study of polytrauma patients with candidemia admitted to the surgical intensive care units of a university hospital in Turkey between 2013 and 2017 on. Results: The incidence of candidemia was 127 episodes per 1000 intensive care unit admissions in polytrauma patients. Non- albicans Candida species accounted for 75.5% of all candidemia episodes. C. parapsilosis (51.05%) was the predominant species, followed by C. albicans (24.52%) and C. tropicalis (12.21%). The highest crude mortality rate (72%) was observed in patients with C. parapsilosis candidemia. In multivariate analyses, who had undergone prior gastrointestinal surgery were 7.1 times more likely to have C. parapsilosis candidemia than those with other strains. Conclusion: Our study, remarkable, demonstrated a high incidence of Candidemia had in polytrauma patients, and non-albicans Candida species were the most frequently isolated candida species. According to our study findings, a prior history of gastrointestinal surgery may help predict C. parapsilosis, as the causative agent of candidemia in polytrauma patients. However, since our study was observational and limited to such a small number of patients, the results obtained should be applied with caution
  • Küçük Resim
    Öğe
    Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3
    (2020) Bal, Tayibe; Cabalak, Mehmet
    Aim: Few studies have evaluated real-world clinical experience with sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotypes 2 and 3 infections from Turkey. Thus, this study aimed to investigate the results of sofosbuvir plus ribavirin therapy in genotype 2 and 3 cases followed in an infectious disease clinic at a university hospital in Hatay, southern Turkey. Material and Methods: In this single-centre, retrospective, observational study, 58 eligible patients treated with SOF/RBV (400 mg of SOF plus weight-based RBV) therapy between October 2016 and February 2019 were examined. Forty-three patients who had completed the duration of treatment and had known virological response status were evaluated for treatment outcomes. Results: SOF/RBV achieves a sustained virological response (SVR) rate of 96.3% and 100% in the HCV genotype 2 and 3 groups, respectively, with treatment duration of 12-24 weeks. No patient experienced a virologic breakthrough while only one experienced virologic relapse after the completion of therapy. The incidence of adverse events was 25.5% (11/43) while the most common (11.6%) adverse event was ribavirin-related hemolytic anemia. Conclusion: The current study revealed that the SOF/RBV therapy achieved excellent response rates with a good safety profile in non-cirrhotic Turkish patients infected with HCV genotype 2 or 3.